Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04412616 · ClinicalTrials.gov registry record · Phase 1
ZZ06 in Adult Patients With Advanced Solid Tumor Malignancies
A Phase 1 study of Advanced EGFR Positive Solid Tumor, sponsored by Changchun Intellicrown Pharmaceutical Co..
- Recruiting
- Registry status
- Phase 1
- Development phase
- 60
- Enrollment target
- 5
- Study locations
NCT04412616 is a Phase 1 study of Advanced EGFR Positive Solid Tumor that is actively recruiting participants, run by Changchun Intellicrown Pharmaceutical Co.. The registered enrollment target is 60 participants. The trial reports 5 study locations across 4 states.
The verdict
NCT04412616, a Phase 1 study of Advanced EGFR Positive Solid Tumor, is actively recruiting participants, sponsored by Changchun Intellicrown Pharmaceutical Co..
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 60 participants
- Enrollment target
- 5
- Study locations
Study Summary
This is a Phase 1, Multicenter, Open-label study to assess the safety, tolerability and preliminary efficacy of ZZ06 in participants with all Adult Patients with Advanced EGFR-positive Solid Tumor Malignancies who are not able to have current standard anti-tumor therapies. The purpose of this study is to determine the maximum tolerated dose (MTD) , to characterise the safety, pharmacokinetics (PK), immunogenicity, pharmacodynamics (PD) and anti-tumor activity of ZZ06 as a single agent in adult participants with advanced solid tumors.
Conditions Studied
Interventions
- BIOLOGICAL ZZ06
Study Locations (5)
Jilin
- Jilin Cancer Hospital - Changchun
- The first Bethune hospital of Jilin University - Changchun
California
- Cedars Sinai Medical Center - Los Angeles
Kansas
- Kansas University Cancer Center - Fairway
New York
- Montefiore Medical Center - The Bronx
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2020-09-01 |
| Est. Completion | 2026-07-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04412616
The ClinicalTrials.gov registry entry for NCT04412616 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Changchun Intellicrown Pharmaceutical Co., which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Advanced EGFR Positive Solid Tumor appearing as the primary indexed condition, and to 1 intervention - of which ZZ06 is the first listed.
NCT04412616 reports 5 study locations spanning 4 distinct geographic areas - top geographies include Jilin, California, Kansas.
Frequently Asked Questions
What is clinical trial NCT04412616 about?
NCT04412616 is a clinical study titled "ZZ06 in Adult Patients With Advanced Solid Tumor Malignancies". This is a Phase 1, Multicenter, Open-label study to assess the safety, tolerability and preliminary efficacy of ZZ06 in participants with all Adult Patients with Advanced EGFR-positive Solid Tumor Malignancies who are not able to have current standard anti-tumor therapies. The purpose of this study ...
What is the current status of trial NCT04412616?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2020-09-01. Estimated completion is 2026-07-06.
What conditions does trial NCT04412616 study?
This clinical trial studies the following conditions: Advanced EGFR Positive Solid Tumor.
What interventions are being tested in trial NCT04412616?
The interventions under investigation include: ZZ06 (BIOLOGICAL).
Who is sponsoring clinical trial NCT04412616?
This trial is sponsored by Changchun Intellicrown Pharmaceutical Co., which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04412616 being conducted?
This trial has 5 study locations across California, Kansas, New York, Jilin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.